Achaogen Inc. (NASDAQ:AKAO) shares traded up 3.1% on Monday . The stock traded as high as $3.70 and last traded at $3.68, with a volume of 94,874 shares traded. The stock had previously closed at $3.57.

Several research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Achaogen from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Wednesday, July 6th. Wedbush upgraded shares of Achaogen from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $7.00 to $10.00 in a research note on Tuesday, June 14th. Needham & Company LLC reiterated a “hold” rating on shares of Achaogen in a research note on Monday, May 9th. Finally, Cowen and Company cut shares of Achaogen from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 31st. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $10.63.

The company’s 50 day moving average price is $3.94 and its 200 day moving average price is $3.69. The firm’s market cap is $70.50 million.

Achaogen, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.